Taking Stock of Current and Emerging Anti-VEGF Therapy Dosing Regimens for nAMD healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
Cantor Fitzgerald reiterated their overweight rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. They currently have a $6.00 price target on the stock. Separately, HC Wainwright restated a buy rating and issued a $7.00 price objective on shares of Lineage Cell […]